Phibro Animal Health (PAHC) Downgraded by ValuEngine

Share on StockTwits

Phibro Animal Health (NASDAQ:PAHC) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Monday.

A number of other research firms have also recently weighed in on PAHC. BidaskClub cut shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Morgan Stanley upped their price objective on shares of Phibro Animal Health from $36.00 to $46.00 and gave the company an “underweight” rating in a research report on Wednesday, August 29th. Finally, Zacks Investment Research raised shares of Phibro Animal Health from a “sell” rating to a “buy” rating and set a $53.00 price objective for the company in a research report on Thursday, August 30th. Four research analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. The stock presently has a consensus rating of “Sell” and a consensus target price of $43.50.

NASDAQ:PAHC opened at $36.56 on Monday. The company has a debt-to-equity ratio of 1.62, a current ratio of 3.26 and a quick ratio of 1.82. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 3.13 and a beta of 0.82. Phibro Animal Health has a 1-year low of $32.05 and a 1-year high of $54.62.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $0.39 earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.03). The firm had revenue of $200.20 million during the quarter, compared to analysts’ expectations of $203.99 million. Phibro Animal Health had a net margin of 7.89% and a return on equity of 38.91%. The business’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.38 earnings per share. As a group, sell-side analysts expect that Phibro Animal Health will post 1.74 earnings per share for the current fiscal year.

In other news, insider Dean J. Warras sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $42.84, for a total value of $428,400.00. Following the sale, the insider now owns 10,000 shares in the company, valued at approximately $428,400. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jack Bendheim sold 30,000 shares of the company’s stock in a transaction dated Thursday, August 23rd. The shares were sold at an average price of $50.04, for a total transaction of $1,501,200.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 93,020 shares of company stock worth $4,481,471. Company insiders own 50.29% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Quantbot Technologies LP acquired a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $115,000. Royal Bank of Canada raised its stake in Phibro Animal Health by 2,104.6% during the first quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock worth $151,000 after acquiring an additional 3,641 shares during the period. Meeder Asset Management Inc. raised its stake in Phibro Animal Health by 149.2% during the second quarter. Meeder Asset Management Inc. now owns 4,470 shares of the company’s stock worth $206,000 after acquiring an additional 2,676 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Phibro Animal Health during the third quarter worth about $206,000. Finally, Piedmont Investment Advisors LLC acquired a new stake in Phibro Animal Health during the second quarter worth about $213,000. Institutional investors and hedge funds own 48.25% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Recommended Story: What is Cost of Debt?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply